Atazanavir (BMS-232632) for HIV Infected Individuals Completing Atazanavir Clinical Trials: An Extended Access Study.

Trial Profile

Atazanavir (BMS-232632) for HIV Infected Individuals Completing Atazanavir Clinical Trials: An Extended Access Study.

Completed
Phase of Trial: Phase III

Latest Information Update: 17 May 2017

At a glance

  • Drugs Atazanavir (Primary) ; Emtricitabine/tenofovir disoproxil fumarate; Ritonavir
  • Indications Acquired immunodeficiency syndrome; HIV infections
  • Focus Adverse reactions
  • Sponsors Bristol-Myers Squibb
  • Most Recent Events

    • 14 Apr 2016 Status changed from active, no longer recruiting to completed.
    • 18 Jun 2012 Actual initiation date changed from Nov 2002 to Jan 2002 as reported by ClinicalTrials.gov.
    • 21 Feb 2012 Additional locations (Puerto Rico, South Africa) added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top